Peptide Therapy Boom Raises New Payments Compliance Challenges

Growing demand for peptide and GLP-1 therapies has left health brands, medical aesthetics clinics and compounding pharmacies increasingly reliant on credit cards and installment financing. With U.S. Food and Drug Administration (FDA) rules still evolving and product sourcing and prescription validity difficult to verify in real time, banks and payment processors may classify legitimate businesses as high-risk merchants.

Financing Your Way cited an American Banker report on July 7, 2026, saying payment providers and lenders had stepped up scrutiny of peptide and GLP-1 merchants. They may raise rates, freeze accounts or suspend medical installment financing. The report did not identify specific banks or processors or disclose the amounts or number of cases affected. Reviews currently focus on product-sourcing records and complete prescription procedures.